ICR researchers develop blood test to uncover how childhood tumours adapt
It is hoped that the approach will lead to more targeted treatments for childhood cancers
Read More
Tag: Institute of Cancer Research
Study reveals new AI tool predicts recurrence of prostate cancer by a decade
The most commonly diagnosed cancer in men in the UK leads to over 12,000 annual deaths
Read More
Study reveals genetic mutations associated with aggressive prostate cancer
Aggressive prostate cancer accounts for up to 15% of all prostate cancer diagnoses
Read More
Collaborators form national NHS patient database registry for Lynch syndrome patients
The genetic condition affects one in 279 people in England and significantly increases cancer risk
Read More
ICR awarded $25m by Cancer Grand Challenges to research solid tumours in children
Globally, cancer is currently the most leading cause of death due to disease among children
Read More
ICR study reveals new targeted immunotherapy to prevent spread of breast cancer
Breast cancer is responsible for around 47,000 new cases in England every year
Read More
Radiotherapy boost shown to reduce treatment times for breast cancer patients
Every year, around 55,000 women in the UK are diagnosed with the condition
Read More
Two charities co-fund £5.5m childhood cancer research programme
SMPaeds2 aims to advance precision medicines for children with relapsed cancer
Read More
AI twice as accurate as a biopsy when grading severity of sarcomas
The new AI model could potentially be applied to other cancers
Read More
High-performance computing could improve therapy for hard-to-treat cancer
Researchers reduced 4D-MRI image reconstruction times to 60 seconds
Read More
Five-drug combination for ultra-high-risk bone marrow cancer identified
A team at The Institute of Cancer Research (ICR), London and the Clinical Trials Research Unit (CTRU) at the University of Leeds adopted a new high-speed trial methodology.
Read More
Multi-drug approach found to attack resistance in bowel cancer
A new study has shown that triple drug combinations could prevent resistance in many cancer types.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
